Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study

Conditions Phase Intervention Type
    Nephrotic Syndrome Nephrosis Nephrosis, Lipoid
4
Drug
Myfortic plus low-dose steroid
Prednisolone

Eligibility

Ages Eligible for Study
18 years to 65 years
Genders Eligible for Study
Both

Keywords

Minimal Change Nephrotic Syndrome, Corticosteroid, Mycophenolate, Remission, and Safety

Sponsors

Other
The University of Hong Kong

Inclusion Criteria

- Male or female 18 - 65 years of age

- First histologic diagnosis of MCNS

- Proteinuria > 3.5 g/day

- Patients who are willing to give written, informed consent

Exclusion Criteria

- Presence of secondary causes of MCNS

- History of glomerular disease including MCNS

- eGFR < 50 ml/min/1.73m2

- Renal histology showing pathologies other than MCNS

- Female of child-bearing age who are unwilling to practice effective contraception

- Patients simultaneously participating in another study or who have participated in
another study within the last 30 days of entry into this study

Detailed Description

Study objective: To investigate the potential therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for minimal change nephrotic syndrome (MCNS).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01185197

Locations

  • Queen Mary Hospital
    Hong Kong, China

    Status: